Kentucky maintains compounding restrictions on six peptides despite federal policy
Kentucky's Board of Pharmacy has declined to waive existing ingredient restrictions for six peptides, maintaining restrictions on compounding and shipments into the state despite the federal enforcement-discretion policy.
A November 19 compliance alert documents the board's November 18 decision to enforce existing state regulations (201 KAR 2:076). The six peptides affected are BPC-157, TB-500, epitalon, semax, KPV and MOTS-c.
According to the board, none meets Kentucky's ingredient eligibility criteria: an applicable US Pharmacopeia or National Formulary monograph, use as a component of an FDA-approved human drug, or inclusion on the FDA's 503A bulks list.
The board maintains that federal enforcement discretion neither changes these criteria nor overrides state law.
The alert directs pharmacies not to compound, dispense or ship affected preparations in or into Kentucky. The requirements also apply to licensed out-of-state pharmacies serving Kentucky customers.
Pharmacies must segregate affected inventory and document ingredient eligibility before compounding.
The decision represents enforcement of existing state regulations rather than the introduction of new restrictions. The board says it will continue to monitor FDA rulemaking.